Overview

Imaging endpoints provide objective measures of disease burden response and progression in clinical trials. Standardized acquisition and centralized reading reduce variability and support regulatory acceptance. Early engagement with sponsors and regulators improves endpoint qualification.

Endpoint Development

Define analytical validity reproducibility and clinical relevance for candidate imaging biomarkers and document performance in pilot studies. Use phantom studies and cross site calibration to ensure measurement consistency. Pre specify analysis plans and thresholds to avoid post hoc bias.

Operational Workflow

Centralized image collection de identification and blinded independent review panels maintain trial integrity and reduce bias. Automated quality checks and standardized reporting templates streamline data flow and monitoring. Timely feedback to sites improves adherence to protocol and image quality.

Regulatory Considerations

Pursue biomarker qualification pathways and engage regulatory agencies early to align on evidence requirements. Provide comprehensive validation data including reproducibility and clinical utility to support labeling claims. Maintain transparent documentation and data access for audits and inspections.